Liquid purification or separation – Processes – Separating
Reexamination Certificate
1999-02-24
2001-01-23
Kim, John (Department: 1723)
Liquid purification or separation
Processes
Separating
C210S435000, C210S436000, C210S472000, C210S483000, C210S488000, C210S489000, C210S503000, C210S504000, C210S505000, C210S506000, C210S507000, C210S508000, C435S002000
Reexamination Certificate
active
06177019
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to the filtration of blood cells and more specifically, to a method for selectively removing tumor cells from tumor cell-contaminated stem cell products. A preferred embodiment of the invention provides a method which relies on an in-line filtration device that includes one or more tumor cell reduction filter pads.
BACKGROUND OF THE INVENTION
Hematopoietic cells are rare, pluripotent cells, having the capacity to give rise to all lineages of blood cells. Through a process referred to as commitment, self-renewing stem cells are transformed into progenitor cells which are the precursors of several different blood cell types, including erythroblasts, myeloblasts and monocyte/macrophages. Due to their self-renewing capacity, stem cells have a wide range of potential applications in transfusion medicine, and in particular, in the autologous support of cancer patients.
Procedures have been developed whereby stem cells can be obtained from a donor, stored and later transplanted into a patient experiencing an immunosuppressive condition, such as following high dose chemotherapy or total body radiation. In the past, stem cells were harvested from bone marrow in a costly and painful procedure which required hospitalization and general anesthesia. New developments in technology, however, now make it possible to derive stem cells and committed progenitor cells from peripheral blood. Collection of stem cell products (SC products), a term which includes both true stem cells and committed progenitor cells (i.e., CD 34
+
cells are included), can thus be done on an outpatient basis, eliminating the need for hospitalization. In addition, stem cell products can also be derived from peripheral blood during elective surgeries.
Once collected, the SC products, whether from bone marrow or peripheral blood, can be stored for future use, one of the most significant of which is transplantation to enhance hematologic recovery following an immunosuppressive procedure such as chemotherapy.
There is, however, one significant drawback to the use of this very beneficial reinfusion procedure. Inevitably, when SC products are obtained from a cancer patient, a significant number of tumor cells will also be collected, thereby contaminating the SC product. Subsequently, when the SC product is reinfused into the patient, the tumor cells are also reintroduced, increasing the concentration of tumor cells in the patient's blood stream. While circulating tumor cells have not been directly linked to the relapse of a particular cancer, in the case of lymphoma, for example, reinfused cells have been traced to sites of disease relapse. In cases involving adenocarcinoma, it has been estimated that for a 50 kilogram adult, approximately 150,000 tumor cells can be reinfused during a single stem cell transplantation. Moreover, it has been shown that the tumor cells present in the SC product are viable and capable of in vitro clonogenic growth, thus suggesting that they could indeed contribute to post-reinfusion relapse. Ovarian cancer cells, testicular cancer cells, breast cancer cells, multiple myeloma cells, non-Hodgkin's lymphoma cells, chronic myelogenous leukemia cells, chronic lymplocytic leukemia cells, acute myeloid leukemia cells, and acute lymphocytic leukemia cells are known to be transplantable.
The extent of tumor cell contamination of SC products appears to vary greatly from patient to patient, and values within the range of 11 to 78 percent have been recorded. Therefore, as the reinfusion of circulating tumor cells may well circumvent the benefits provided by aggressive chemotherapy followed by stem cell transplantation, the development of techniques that effectively remove tumor cells from SC products will significantly further the widespread use of a very beneficial and valuable clinical procedure.
Methods currently used to separate the valuable stem cells from the undesired tumor cell-contaminated product rely on a positive selection technique that identifies stem cells and progenitor cells that express markers for the CD34
+
antigen and remove them from the contaminated product. These methods are very labor intensive and require the use of specialized equipment, thus greatly increasing the cost of patient care and severely limiting the use of SC products in transplantation procedures.
An alternative to positive selection for removal of tumor cells from blood was provided by Gudemann et al., who described filtration with special leukocyte depletion membrane filters (which work by adsorbing charged particles) to remove urologic tumor cells from autologous blood during an intraoperative mechanical autotransfusion (IAT) procedure. (Gudemann, C., Wiesel, M. and Staehler, G.,
Intraoperative Autotransfusion In Urologic Cancer Surgery By Using Membrane Filters
, XXIII
rd
Congress of the ISBT, abstracts in Vox Sang., 67 (S2), 22.) A disadvantage of the membrane filters used by Gudemann el al is that they do not selectively retain tumor cells. White blood cells, including stem cells, are also retained. Thus, tumor cells are not removed from stem cells.
The work of Miller et al also teaches that standard blood transfusion filters are ineffective at removing tumor cells from autologous blood. (Miller, G. V., Ramsden, C. W. and Primrose, J. N.,
Autologous transfusion: an alternative to transfusion with banked blood during surgeryfor cancer
, B. J. Surg. 1991, Vol. 78, Jun., 713-715).
It is therefore desirable, based upon the valuable benefits achieved by the transplantation of previously obtained stem cell products, benefits that ultimately result in increased survival rates, to provide a low-cost, clinically effective method for the selective removal of tumor cells from tumor cell-contaminated stein cell products.
SUMMARY OF THE INVENTION
The present invention provides a low-cost, clinically effective method for selectively removing tumor cells from a tumor cell-contaminated stem cell (TCCSC) product while allowing for optimal recovery of hematopoietic stem cells and committed progenitor cells.
Thus, one aspect of the invention is a method for removing tumor cells from a tumor cell-contaminated stem cell product, comprising the steps of:
(a) providing an in-line filtration device including:
a housing having an inlet port and an outlet port therein; and
a tumor cell reduction filter means disposed within said housing between the inlet port and the outlet port so as to filter tumor cell-contaminated stem cell products which flow into the filtration device via the inlet port, said tumor cell reduction filter means dividing said housing into a first chamber and a second chamber;
(b) providing a tumor cell-contaminated stein cell product;
(c) passing the tumor cell-contaminated stem cell product through the filtration device wherein tumor cells are retained by the tumor cell reduction filter means within the filtration device and the stem cell product passes through the tumor cell reduction filter means and out of the filtration device; and
(d) recovering a tumor cell-depleted stem cell product.
Preferably, the tumor cell reduction filter means provides at least a 10-fold unit reduction in tumor cells and at least a 30% recovery (more preferably a 50% recovery) of stem cells in the tumor-cell depleted stem cell product, and the flow rate of stem cell product through the filter means will be at least 50 mL per hour. To provide optimal tumor cell retention and stem cell recovery, the filter means has an air permeability of at least about 750 L/min to about 1×10
4
L/min.
Thus, one embodiment of the invention provides a device suitable for use as a tumor cell reduction filter means in an in-line filtration device wherein the tumor cell reduction filter means provides at least a ten-fold reduction in tumor cells and at least a 30% recovery of stem cells in a filtered stem cell product. Preferably the tumor cell reduction filter means provides a stein cell product flow rate of at least 50 mL per hour and has an air permeability of at least about 750 Llmin
Castino Franco
Wickramasinghe Sumith R.
Hemasure Inc.
Heslin & Rothenberg, P.C.
Kim John
LandOfFree
Method and apparatus for removing tumor cells from tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and apparatus for removing tumor cells from tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and apparatus for removing tumor cells from tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2465675